EP3192517A4 - Method for enhancing immune cell function and method for assessing immune cell multifunctionality - Google Patents

Method for enhancing immune cell function and method for assessing immune cell multifunctionality Download PDF

Info

Publication number
EP3192517A4
EP3192517A4 EP15833898.8A EP15833898A EP3192517A4 EP 3192517 A4 EP3192517 A4 EP 3192517A4 EP 15833898 A EP15833898 A EP 15833898A EP 3192517 A4 EP3192517 A4 EP 3192517A4
Authority
EP
European Patent Office
Prior art keywords
immune cell
multifunctionality
assessing
enhancing
cell function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15833898.8A
Other languages
German (de)
French (fr)
Other versions
EP3192517A1 (en
Inventor
Heiichiro Udono
Shingo EIKAWA
Shin-ichi TOYOOKA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Okayama University NUC
Original Assignee
Okayama University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Okayama University NUC filed Critical Okayama University NUC
Priority to EP17174222.4A priority Critical patent/EP3232199B1/en
Publication of EP3192517A1 publication Critical patent/EP3192517A1/en
Publication of EP3192517A4 publication Critical patent/EP3192517A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/55—IL-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
EP15833898.8A 2014-08-19 2015-08-17 Method for enhancing immune cell function and method for assessing immune cell multifunctionality Withdrawn EP3192517A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP17174222.4A EP3232199B1 (en) 2014-08-19 2015-08-17 Combination of immunosuppressive factor blocking agent and biguanide antidiabetic drug for use in a method of preventing progression of, treating and/or preventing cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014166593 2014-08-19
JP2015085556 2015-04-20
PCT/JP2015/073011 WO2016027764A1 (en) 2014-08-19 2015-08-17 Method for enhancing immune cell function and method for assessing immune cell multifunctionality

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP17174222.4A Division-Into EP3232199B1 (en) 2014-08-19 2015-08-17 Combination of immunosuppressive factor blocking agent and biguanide antidiabetic drug for use in a method of preventing progression of, treating and/or preventing cancer
EP17174222.4A Division EP3232199B1 (en) 2014-08-19 2015-08-17 Combination of immunosuppressive factor blocking agent and biguanide antidiabetic drug for use in a method of preventing progression of, treating and/or preventing cancer

Publications (2)

Publication Number Publication Date
EP3192517A1 EP3192517A1 (en) 2017-07-19
EP3192517A4 true EP3192517A4 (en) 2018-04-25

Family

ID=55350709

Family Applications (2)

Application Number Title Priority Date Filing Date
EP15833898.8A Withdrawn EP3192517A4 (en) 2014-08-19 2015-08-17 Method for enhancing immune cell function and method for assessing immune cell multifunctionality
EP17174222.4A Active EP3232199B1 (en) 2014-08-19 2015-08-17 Combination of immunosuppressive factor blocking agent and biguanide antidiabetic drug for use in a method of preventing progression of, treating and/or preventing cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP17174222.4A Active EP3232199B1 (en) 2014-08-19 2015-08-17 Combination of immunosuppressive factor blocking agent and biguanide antidiabetic drug for use in a method of preventing progression of, treating and/or preventing cancer

Country Status (15)

Country Link
US (2) US20170231929A1 (en)
EP (2) EP3192517A4 (en)
JP (3) JP6629211B2 (en)
KR (1) KR20170042778A (en)
CN (1) CN107148274A (en)
AU (1) AU2015304448B2 (en)
BR (1) BR112017002807A2 (en)
CA (1) CA2958573A1 (en)
ES (1) ES2915849T3 (en)
IL (1) IL250639B (en)
MX (1) MX2017002134A (en)
PH (1) PH12017500224A1 (en)
RU (2) RU2020127099A (en)
SG (2) SG10202005315SA (en)
WO (1) WO2016027764A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117534755A (en) * 2005-05-09 2024-02-09 小野药品工业株式会社 Human monoclonal antibodies to programmed death-1 (PD-1) and methods of treating cancer using anti-PD-1 antibodies
EA035037B1 (en) 2013-12-12 2020-04-21 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
CA3037380A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
CN107082812B (en) 2017-03-29 2018-11-13 上海科医联创生物科技有限公司 It is a kind of restore debilitating immune cell function fusion protein and its application
LT3630112T (en) * 2017-06-02 2024-05-10 Bayer Healthcare Llc Combination of regorafenib and nivolumab for treating cancer
WO2019069449A1 (en) * 2017-10-06 2019-04-11 純児 赤木 Measurement method
WO2019124423A1 (en) * 2017-12-19 2019-06-27 国立大学法人 岡山大学 Agent for progression suppression, treatment, prophylaxis and/or recurrence prevention of cancer
JP2019112353A (en) * 2017-12-25 2019-07-11 合同会社チューモス Autologous tumor vaccine and immune induction method
US11959916B2 (en) * 2017-12-26 2024-04-16 Tamio Yamauchi Method, system, and program for supplying immunodynamics-related information
KR102338992B1 (en) * 2018-01-05 2021-12-14 지엔티 바이오테크 & 메디컬즈 코포레이션 A pharmaceutical combination and method for regulation of tumor microenvironment and immunotherapy
WO2019202473A1 (en) * 2018-04-16 2019-10-24 Université de Lausanne Ucp2 inducing agents for the treatment of cancer resistant to immune checkpoint blockade
US20220017969A1 (en) * 2018-12-07 2022-01-20 Arizona Board Of Regents On Behalf Of The University Of Arizona A method of determining risk for skin cancer development and skin cancer therapeutic prevention by measuring pd-1/pd-l1 signaling pathway members
KR102510381B1 (en) * 2019-10-16 2023-03-15 한국과학기술원 An Immunotherapeutic agent composition for preventing or treating brain cancer comprising metformin as an active reagent
WO2022072745A1 (en) * 2020-10-01 2022-04-07 The Regents Of The University Of California Methods and compositions to treat and prevent viral infections and acute respiratory distress syndrome
CN112791182A (en) * 2020-12-31 2021-05-14 中山大学 Application of pharmaceutical composition of metformin and anti-PD-1 antibody in preparation of liver cancer drugs
CN113421627B (en) * 2021-05-11 2023-04-07 深圳市罗湖区人民医院 System for evaluating anti-aging effect of drug on NK (natural killer) cells in vitro

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011031474A2 (en) * 2009-08-25 2011-03-17 President And Fellows Of Harvard College Use of metformin in cancer treatment and prevention
WO2012095379A1 (en) * 2011-01-11 2012-07-19 Universität Basel Combination of syrosingopine and mitochondrial inhibitors for the treatment of cancer and immunosuppression
JP2014214093A (en) * 2013-04-23 2014-11-17 国立大学法人岡山大学 Function improving agent for immune exhaustion cd8+t cell, cancer therapeutic agent, and metabolic syndrome preventive or therapeutic agent

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5260275A (en) * 1990-08-14 1993-11-09 Amylin Pharmaceuticals, Inc. Hypoglycemics
NZ275711A (en) * 1993-10-14 1998-03-25 Immunex Corp Monoclonal antibodies and binding proteins which bind to human fas antigen (nerve growth factor/tumour necrosis factor receptor type)
EP1387675A2 (en) * 2000-08-07 2004-02-11 Ranbaxy Signature LLC Liquid formulation of metformin
JP4409430B2 (en) * 2002-07-03 2010-02-03 小野薬品工業株式会社 Immunostimulatory composition
CN117534755A (en) 2005-05-09 2024-02-09 小野药品工业株式会社 Human monoclonal antibodies to programmed death-1 (PD-1) and methods of treating cancer using anti-PD-1 antibodies
WO2009030257A1 (en) * 2007-09-05 2009-03-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Methods and compounds for treating diseases caused by reactive oxygen species
US20130059916A1 (en) * 2010-05-26 2013-03-07 Stephane Rocchi Biguanide compounds and its use for treating cancer
EP2729174A1 (en) * 2011-07-08 2014-05-14 Merck Sharp & Dohme Corp. Il-23 antagonists for treatment or prevention of skin rash associated with treatment with p13k/akt pathway inhibitors
CN103371991A (en) * 2012-04-18 2013-10-30 中国人民解放军第二军医大学 Application of dimethyldiguanide in preparation of medicaments for preventing or treating hepatocellular carcinoma
NO2872646T3 (en) * 2012-07-12 2018-01-27
EP3470531A1 (en) * 2012-08-06 2019-04-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for screening patients with a cancer
SG11201502496WA (en) * 2012-10-02 2015-04-29 Bristol Myers Squibb Co Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
WO2014083095A1 (en) * 2012-11-29 2014-06-05 Universitaet Basel Combinations of metformin with other compounds for the treatment of cancer and for immunosuppression
PT2941258T (en) * 2013-01-02 2019-12-12 Decoy Biosystems Inc Compositions and methods for treatment of cancer using bacteria

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011031474A2 (en) * 2009-08-25 2011-03-17 President And Fellows Of Harvard College Use of metformin in cancer treatment and prevention
WO2012095379A1 (en) * 2011-01-11 2012-07-19 Universität Basel Combination of syrosingopine and mitochondrial inhibitors for the treatment of cancer and immunosuppression
JP2014214093A (en) * 2013-04-23 2014-11-17 国立大学法人岡山大学 Function improving agent for immune exhaustion cd8+t cell, cancer therapeutic agent, and metabolic syndrome preventive or therapeutic agent

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DAVID A CHRISTIAN ET AL: "Particle-mediated delivery of cytokines for immunotherapy", IMMUNOTHERAPY, vol. 4, no. 4, 1 April 2012 (2012-04-01), GB, pages 425 - 441, XP055224065, ISSN: 1750-743X, DOI: 10.2217/imt.12.26 *
HEIICHIRO UDONO: "Metohorumin ni yoru shuyo kyokusho no men'eki hihei kaijo [Metformin-induced reversion of exhausted T cells in tumor microenvironment]", DAI 12 KAI JAPAN RESEARCH ASSOCIATION FOR IMMUNOTHERAPEUTICS GAKUJUTSU SHUKAI; 28/02/2015, JAPAN RESEARCH ASSOCIATION FOR IMMUNOTHERAPEUTICS, JP, vol. 12th, 16 February 2015 (2015-02-16), pages 22, XP008185836 *
HEIICHIRO UDONO: "Shuyo Kyokusho ni Okeru Men'eki Hihei to sono Kaijo ni yoru Ko Shuyo Men'eki Oto [Immune exhaustion in the tumor locus and antitumor immune response by its release]", DAI 17 KAI JAPANESE ASSOCIATION OF CANCER IMMUNOLOGY SOKAI PROGRAM SHOROKUSHU; JULY 3-5,2013; UBE, YAMAGUCHI, JAPAN, JAPANESE ASSOCIATION OF CANCER IMMUNOLOGY, JP, vol. 17th, 10 June 2013 (2013-06-10), pages 36, XP008185837 *
MICHAEL POLLAK: "Potential applications for biguanides in oncology", JOURNAL OF CLINICAL INVESTIGATION, vol. 123, no. 9, 3 September 2013 (2013-09-03), US, pages 3693 - 3700, XP055460068, ISSN: 0021-9738, DOI: 10.1172/JCI67232 *
See also references of WO2016027764A1 *
SHINGO EIKAWA ET AL: "Immune-mediated antitumor effect by type 2 diabetes drug, metformin", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, vol. 112, no. 6, 26 January 2015 (2015-01-26), US, pages 1809 - 1814, XP055400393, ISSN: 0027-8424, DOI: 10.1073/pnas.1417636112 *
SHINGO EIKAWA ET AL: "OS15-5 Shuyo Kyokusho ni Okeru Men'eki Hihei CD 8T Saibo no Kino Kaifuku o Kaishita Metformin no Ko Shuyo Koka", DAI 17 KAI JAPANESE ASSOCIATION OF CANCER IMMUNOLOGY SOKAI PROGRAM SHOROKUSHU, JAPANESE ASSOCIATION OF CANCER IMMUNOLOGY, JP, vol. 17th, 10 June 2013 (2013-06-10), pages 114, XP008185850 *
SHINGO EIKAWA: "2-gata Tonyobyoyaku Metformin no Shuyo Kyokusho ni Okeru CD 8T Saibo Hihei Kaijo", DAI 9 KAI THE BIOMEDICAL SOCIETY FOR STRESS RESPONSE TAIKAI SHOROKUSHU, THE BIOMEDICAL SOCIETY FOR STRESS RESPONSE, JP, vol. 9th, 1 November 2014 (2014-11-01), pages 51, XP008185851 *

Also Published As

Publication number Publication date
JP2017165752A (en) 2017-09-21
JP6629211B2 (en) 2020-01-15
SG11201700978SA (en) 2017-03-30
PH12017500224B1 (en) 2017-07-10
JP2020109098A (en) 2020-07-16
RU2731098C2 (en) 2020-08-28
RU2017108754A3 (en) 2019-03-29
EP3192517A1 (en) 2017-07-19
PH12017500224A1 (en) 2017-07-10
EP3232199B1 (en) 2022-05-04
BR112017002807A2 (en) 2017-12-19
KR20170042778A (en) 2017-04-19
US20170281569A1 (en) 2017-10-05
US20170231929A1 (en) 2017-08-17
EP3232199A3 (en) 2018-02-14
RU2017108754A (en) 2018-09-20
IL250639A0 (en) 2017-04-30
SG10202005315SA (en) 2020-07-29
CA2958573A1 (en) 2016-02-25
WO2016027764A1 (en) 2016-02-25
RU2020127099A (en) 2020-09-02
JP6672217B2 (en) 2020-03-25
AU2015304448A1 (en) 2017-03-09
EP3232199A2 (en) 2017-10-18
JPWO2016027764A1 (en) 2017-06-01
IL250639B (en) 2020-02-27
ES2915849T3 (en) 2022-06-27
EP3232199A8 (en) 2017-12-13
AU2015304448B2 (en) 2020-04-30
MX2017002134A (en) 2017-09-13
CN107148274A (en) 2017-09-08

Similar Documents

Publication Publication Date Title
IL250639B (en) Method for enhancing immune cell function and method for assessing immune cell multifunctionality
HK1243333A1 (en) Methods and compositions for modified t cells
HK1255101A1 (en) Methods for obtaining regulatory t cells and uses thereof
EP3101751A4 (en) Quick-charging method and system
EP3092318A4 (en) Methods for defining and predicting immune response to allograft
EP3136832A4 (en) Load measurement method and recovery method
EP3101760A4 (en) Charging method and system
EP3113684A4 (en) Method and system for assessing motion symptoms
EP3190599A4 (en) Charging method and device
EP3192861A4 (en) Cell culture evaluation system and cell culture evaluation method
EP3051636A4 (en) Connector and method for realizing connector
EP3107996A4 (en) Tscm cells and methods for use
EP3137629A4 (en) Compositions and methods for detecting huanglongbing
EP3195935A4 (en) Particle charger
EP3127078A4 (en) Method and system for obtaining credit
EP3192295A4 (en) Method and arrangement for cell combination
EP3174377A4 (en) Inspection method
EP3170629A4 (en) Inspection method
HK1221307A1 (en) System for providing interface and method for providing interface
EP2974745C0 (en) Method for immune cell tracking
GB201415338D0 (en) Cell processing method
EP3163842A4 (en) Cloud contact centre and cloudization method for contact centre
EP3149023A4 (en) Protein Extraction Methods
EP3131004A4 (en) Processor and method
EP3213272A4 (en) System and Method for Configuration-Managed Lifecycle Diagrams

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170222

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1233526

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20180326

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/00 20060101ALI20180320BHEP

Ipc: A61P 37/02 20060101ALI20180320BHEP

Ipc: A61K 35/17 20150101AFI20180320BHEP

Ipc: A61P 35/00 20060101ALI20180320BHEP

Ipc: G01N 33/53 20060101ALI20180320BHEP

Ipc: A61P 37/04 20060101ALI20180320BHEP

Ipc: G01N 33/48 20060101ALI20180320BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20190125

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20230301

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1233526

Country of ref document: HK